12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MM-121: Completed Phase II enrollment

Merrimack completed enrollment of 100 patients with triple-negative breast cancer (TNBC) in the second of 2 cohorts in an open-label, U.S. Phase II trial comparing weekly IV MM-121 plus paclitaxel vs. paclitaxel alone for 12 weeks followed by...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >